1. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy
- Author
-
Büyükkaramikli, N., Blommestein, H.M. (Hedwig), Riemsma, R. (Rob), Armstrong, N. (Nigel), F.J. Clay (Fiona), Ross, J. (Janine), Worthy, G. (Gill), Severens, J.L. (Hans), Kleijnen, J.M.P. (Jos), Al, M.J. (Maiwenn), Büyükkaramikli, N., Blommestein, H.M. (Hedwig), Riemsma, R. (Rob), Armstrong, N. (Nigel), F.J. Clay (Fiona), Ross, J. (Janine), Worthy, G. (Gill), Severens, J.L. (Hans), Kleijnen, J.M.P. (Jos), and Al, M.J. (Maiwenn)
- Abstract
The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ramucirumab (Cyramza®, Eli Lilly and Company) to submit evidence of the clinical and cost effectiveness of the drug administered alone (monotherapy) or with paclitaxel (combination therapy) for treating adults with advanced gastric cancer or gastro-oesophageal junction (GC/GOJ) adenocarcinoma that were previously treated with chemotherapy, as part of the Institute’s single technology appraisal (STA) process. Kleijnen Systematic Reviews Ltd (KSR), in collaboration with Erasmus University Rotterdam, was commissioned to act as the Evidence Review Group (ERG). This paper describes the company’s submission, the ERG review, and NICE’s subsequent decisions. Clinical effectiveness evidence for ramucirumab monotherapy (RAM), compared with best supportive care (BSC), was based on data from the REGARD trial. Clinical effectiveness evidence for ramucirumab combination therapy (RAM + PAC), compared with paclitaxel monotherapy (PAC), was based on data from the RAINBOW trial. In addition, the company undertook a network meta-analysis (NMA) to compare RAM + PAC with BSC and docetaxel. Cost-eff
- Published
- 2017
- Full Text
- View/download PDF